GlassScriptPhysician profile
John R Sobotka
NPI 1154412161
$6,425.99
in general payments reported to CMS, 2019-2025
25 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $1,021 · 2023: $1,026 · 2024: $1,678 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,380 · Education: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,380.19 |
| Education | $302.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $871.53 | 2021-2025 | |
| Abbvie INC. | $868.39 | 2021-2025 | |
| Janssen Biotech, INC. | $865.27 | 2021-2025 | Tremfya, Stelara, Remicade |
| Sun Pharmaceutical Industries INC. | $724.58 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $586.94 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $318.19 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $298.47 | 2021-2025 | Dupixent |
| Pfizer INC. | $293.79 | 2021-2025 | |
| Revance Therapeutics, INC. | $251.79 | 2024 | Daxxify |
| Leo Pharma INC. | $242.62 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $203.97 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $191.88 | 2021-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.48 | 2023-2024 | Cyltezo, Spevigo |
| Amgen INC. | $122.47 | 2022-2025 | Otezla, Otezla |
| Lnhc, INC | $102.07 | 2025 | Zelsuvmi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $86.35 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $56.28 | 2023 | Vtama |
| Biofrontera INC. | $41.11 | 2021 | |
| Almirall LLC | $38.53 | 2024 | Seysara |
| Galderma Laboratories, L.P. | $36.45 | 2025 | Nemluvio |
| Ucb, INC. | $31.91 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.34 | 2021 | |
| Organon LLC | $19.81 | 2025 | Vtama |
| Journey Medical Corporation | $15.57 | 2022 | |
| Dermira, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sobotka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.